

Supplementary Material

Self-Management Systems for Patients and Clinicians in Parkinson’s Disease Care: A Scoping Review

Supplementary Table 1. PRISMA-ScR (Preferred Reporting Items for Systematic review and Meta-Analyses extension for Scoping Reviews) 2022 checklist

| SECTION | ITEM | PRISMA-ScR CHECKLIST ITEM | REPORTED ON PAGE # |
|--|------|--|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a scoping review. | 1 |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives. | 2 |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach. | 3 |
| Objectives | 4 | Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives. | 3 |
| METHODS | | | |
| Protocol and registration | 5 | Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number. | 5 |
| Eligibility criteria | 6 | Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale. | 6 |
| Information sources* | 7 | Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed. | 6 |
| Search | 8 | Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. | 35-36 |
| Selection of sources of evidence† | 9 | State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. | 6, 7 |
| Data charting process‡ | 10 | Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators. | 7 |
| Data items | 11 | List and define all variables for which data were sought and any assumptions and simplifications made. | 7 |
| Critical appraisal of individual sources of evidence | 12 | If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate). | 7 |
| Synthesis of results | 13 | Describe the methods of handling and summarizing the data that were charted. | 6-7 |
| RESULTS | | | |
| Selection of sources of evidence | 14 | Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram. | 8 |
| Characteristics of sources of evidence | 15 | For each source of evidence, present characteristics for which data were charted and provide the citations. | 9-14 |

| | | | |
|---|----|---|-------|
| Critical appraisal within sources of evidence | 16 | If done, present data on critical appraisal of included sources of evidence (see item 12). | 14-20 |
| Results of individual sources of evidence | 17 | For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives. | 14-20 |
| Synthesis of results | 18 | Summarize and/or present the charting results as they relate to the review questions and objectives. | 9-20 |
| DISCUSSION | | | |
| Summary of evidence | 19 | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | 20-21 |
| Limitations | 20 | Discuss the limitations of the scoping review process. | 22 |
| Conclusions | 21 | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | 23-24 |
| FUNDING | | | |
| Funding | 22 | Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review. | 24 |

Supplementary Table 2. Endnote search criteria

| Pass^a | Search string | # of references remaining |
|-------------------------|--|----------------------------------|
| 0 | All Results | 15,231 |
| 1 | Duplicates removed | 13,548 |
| 2 | Reference Type = NOT (protocol OR editorial OR conference OR conference proceedings OR perspective paper) | 13,401 |
| 3 | Title OR Abstract = (Parkinson's disease OR parkinson OR parkinson's OR parkinson disease) | 7,526 |
| 4 | Any Field = (electronic OR software OR wearable OR computer OR platform OR system OR telehealth OR home-based OR online OR device | 5,795 |
| 4b | Any Field = (digital OR technology OR remote OR portal OR telemedicine OR web OR internet OR ehealth OR mhealth OR mobile | |
| 6 | Any Field = (self-manag OR monitor OR self manag OR self-care OR database OR rehabilitation OR program OR data management OR data collection OR intervention | 4,123 |
| 7 | Any Field = (evaluat OR assess OR adherence OR efficiency OR efficacy OR attitude OR usability OR feasibility OR impact OR accept | 3,908 |
| 8 | Any Field = NOT (neuro OR cancer OR mutation OR depression OR genetic OR adipose OR molecular OR insulin OR biomarker | 3,396 |
| 9 | Any Field = NOT (deep brain OR plasma OR tuberculosis OR animal OR mice OR rats OR mouse OR metabol OR gene) | 1,644 |
| 10 | Any Field = NOT (polymorph OR transcranial OR adenosine OR rasagiline OR morphine OR alcohol OR arthritis | 1,583 |

^aEach pass was conducted on the subset of studies retrieved in the previous pass

^bEndNote limits searches to 10 terms, so passes 4 and 5 were conducted separately and then combined, with duplicates removed

| Pass^a | Search string | # of references remaining |
|-------------------------|---|----------------------------------|
| Screening in Rayyan | | |
| 10 | Duplicates removed in Rayyan (n = 82) | 1,501 |
| 11 | Title and abstract screening in Rayyan (excluded n=1,409) | 92 |

Supplementary Table 3. Search strings of sample search

| Database | Search String | Retrieved |
|---------------------|--|-----------|
| PubMed | ((("Parkinson disease"[MeSH Terms]) OR ("parkinsons") OR ("Parkinsonism" OR ("parkinson's") OR ("parkinsonian disorders"[MeSH Terms]))) AND ((telemedicine[MeSH Terms]) OR ("internet-based intervention") OR ("digital health") OR ("remote") OR ("home-based") OR ("electronic") OR ("technology") OR ("software") OR ("m-health") OR ("computing methodologies") OR ("system") OR ("self-management system") OR ("portal") OR ("computing methodologies"[MeSH Terms]) OR ("e-health") OR ("wearable electronic devices"[MeSH Terms]) OR ("self-help devices")))) AND (evaluation) | 6,041 |
| CINAHL | AB (parkinson disease or parkinson and disease or parkinson disease or parkinson's disease) AND TX (software or system or remote or portal or technology or digital health or telemedicine or telehealth or ehealth or e-health or mhealth or m-health) AND TX (evaluation or analysis or perspective or attitude or user-experience or acceptability or usability or perspective or UX or barriers or perception) | 5,172 |
| Scopus | TITLE-ABS-KEY (("Parkinson disease" OR "parkinsonian disorders" OR "parkinsons") AND ("telemedicine" OR "digital health" OR "internet-based intervention" OR "remote" OR "home-based" OR "wearable electronic devices" OR "computing methodologies" OR "electronic" OR "technology" OR "software" OR "m-health" OR "system" OR "portal" OR "e-health" OR "self-help devices") AND ("attitude" OR "user-experience" OR "acceptability" OR "usability" OR "perspective" OR "UX" OR "barriers" OR "perception")) | 7,820 |
| ACM digital library | [[Full Text: "parkinson disease"] OR [Full Text: "parkinson's disease"] OR [Full Text: "parkinsonian disorders"]OR [Full Text: "parkinsons"] OR [Full Text: "parkinson"]] AND [[Full Text: "telemedicine"] OR [Full Text: "digital health"] OR [Full Text: "internet-based intervention"] OR [Full Text: "remote"] OR [Full Text: "home-based"] OR [Full Text: "wearable electronic devices"] OR [Full Text: "computing methodologies"]OR [Full Text: "electronic"] OR [Full Text: "technology"] OR [Full Text: "software"] OR [Full Text: "m-health"] OR [Full Text: "system"] OR [Full Text: "portal"] OR [Full Text: "e-health"] OR [Full Text: "self-help devices"] OR [Full Text: "mhealth"]] AND [[Full Text: "evaluation"] OR [Full Text: "attitude"] OR [Full Text: "user-experience"] OR [Full Text: "acceptability"] OR [Full Text: "usability"] OR [Full Text: "perspective"] OR [Full Text: "ux"] OR [Full Text: "barriers"] OR [Full Text: "perception"]] | 1,855 |
| IEEE Xplore | ("All Metadata": "Parkinson disease" OR "All Metadata": "parkinsonian disorders" OR "All Metadata": "parkinsons") AND ("All Metadata": telemedicine OR "All Metadata": digital OR "All Metadata": remote OR "All Metadata": internet OR "All Metadata": electronic OR "All Metadata": technology OR "All Metadata": software OR "All Metadata": system OR "All Metadata": portal OR "All Metadata": "e-health" OR "All Metadata": "m-health" OR "All Metadata": "self-help devices" OR "All Metadata": "internet-based intervention" OR "All Metadata": "remote") AND ("All Metadata": evaluation OR "All Metadata": attitude OR "All Metadata": user OR "All Metadata": acceptability OR "All Metadata": usability OR "All Metadata": perspective) | 222 |

Supplementary Table 4. Summary of study characteristics for included articles

| Author | Year | Study type | Name of system | Symptom category | Outcomes examined | Study method | Evaluation method |
|-----------------------|------|--------------------------------|---------------------------------------|---------------------------------|--|--------------|---|
| Albani et al [69] | 2019 | Experimental Study | Not reported | Motor symptoms | Validity, Accuracy, Usability | Mixed | <ul style="list-style-type: none"> · Accuracy: Specialists assessment based on patient videos recordings · Usability: A study-specific questionnaire of 19-items related to ease of use, learnability, effectiveness, simplicity, adequacy, and availability of information and feeling about the user interface. |
| Beijer et al. [51] | 2010 | Case Study | EST (e-learning based speech therapy) | Motor symptoms: Speech training | Intelligibility, Satisfaction | Mixed | <p>Intelligibility: 20 untrained listeners orthographically transcribed SUS sentences recorded at different times</p> <p>Listening ratings for each SUS sentence on a 10-point scale (1 = extremely bad intelligibility to 10 = extremely good intelligibility. Randomized Block Design: Time as a within-subject factor (five levels).</p> <p>Satisfaction: Study-specific questionnaire captured qualitative information on individual experiences with EST using a 10-point scale.</p> |
| Bendig et al. [41] | 2022 | Observational Study | Not reported | Motor and non-motor symptoms | Usability, Confidence, Independence | Mixed | System Usability Scale (SUS) and compared with empirical confidence scores (patient-rated) and the task-based independence scores (investigator-rated) |
| Brown et al. [26] | 2022 | Survey Study | PD-Bridge | Motor and non-motor symptoms | Usability, Validity, Clinical Relevance, Confidence, Independence, Clinician Experience | Mixed | <p>Usability, Validity/ Clinical Relevance: Focus Groups using System Usability Scale (SUS)</p> <p>Confidence, Independence: Empirical comparison of confidence scores (patient-rated) and task-based independence scores (investigator-rated)</p> <p>Clinician Experience: Study-specific survey with clinicians</p> |
| Chang et al. [53] | 2023 | Prospective, Comparative Study | Not reported | Motor symptoms: Speech training | Acoustic measurement, Auditory-perceptual assessment, Voice handicap index, Satisfaction | Mixed | <p>Acoustic measurement: Maximum phonation time (MPT), mean fundamental frequency (F₀), jitter, shimmer, and noise-to-harmonic ratio (NHR)</p> <p>Auditory-perceptual assessment by speech therapists. Each parameter was rated on a five-point scale, from 0 (normal) to 4 (severe impairment).</p> <p>Voice handicap index: VHI questionnaire of 10 items (K-VHI10)</p> <p>Satisfaction: Qualitative five-point scale survey</p> |
| Chaudhuri et al. [55] | 2022 | Modelling Study | Parkinson's KinetiGraph (PKG) | | Cost-Utility, Comparison of PD progression | Mixed | <p>Cost-utility model: De Novo Markov Model</p> <p>Assessment methods: Comparison of MDS-UPDRS II and III scores</p> |
| Connor et al [27] | 2020 | RCT | | | Knowledge of PD self-care and helpfulness of nurse care | Mixed | <ul style="list-style-type: none"> · Routine assessments of 140 participants through the CHAPS Assessment, 6-month follow-ups, and annual reassessments. |

| | | | | | | | |
|----------------------|------|------------------------------------|--|--|---|-------|--|
| | | | | | managers, perceptions of the CHAPS Assessment, health care Notebook, nurse care manager and PD specialist knowledge, beliefs, and attitudes about CHAPS and their perceptions of participants' self-management, Usability | | <ul style="list-style-type: none"> · Knowledge of PD self-care and helpfulness of nurse care managers + perceptions of the CHAPS Assessment + health care Notebook: 14-item anonymous paper surveys about the CHAPS intervention. · Usability: For PD specialists, additional questions asked about awareness of the Siebens Domain Management Model in the CHAPS documentation. If they responded "yes," then they were asked if they felt it was a helpful way to organize participants' problems/issues (yes, no, unsure). |
| Debelle et al. [69] | 2013 | Cross-sectional study | | | Medication adherence, feasibility, Usability | Mixed | <ul style="list-style-type: none"> · Feasibility + Adherence: Smartwatch, inertial measurement unit, and smartphone. Daily · Usability: Study-specific Questionnaire |
| Dorsey et al [52] | 2010 | Randomized, controlled pilot trial | | | Feasibility, QoL, Satisfaction, Motor Performance, Mood, Cognition | Mixed | In-person evaluations, and motor examination assessed by one of the study physicians, a cognitive examination and multiple self-report questionnaires regarding QoL, satisfaction and depression. |
| Erb et al. [28] | 2020 | Observational study | | | Utility/Reliability, Agreement on the presence of motor complications, Ability of video raters to accurately assess motor symptoms, Dynamics of tremor, dyskinesia, and bradykinesia | Mixed | <ul style="list-style-type: none"> · Utility/ Reliability: Self-Reports for Motor Fluctuations + Evaluation of completion rates and timing of entries + Questionnaires of Likert scales or categorical responses · Agreement Between Participants and Clinical Raters: Applied part III of the MDS-UPDRS by PD specialists · Ability of Video Raters to Assess Motor Symptoms: Utilized a linear mixed model to fit MDS-UPDRS part III total scores. · Dynamics of Tremor, Dyskinesia, and Bradykinesia: Administration of MDS-UPDRS |
| Ferreira et al. [70] | 2015 | Feasibility and Usability Study | | | Acceptability, Adherence, Usability | Mixed | <ul style="list-style-type: none"> · Acceptability + Adherence: Calculated number of participants who discontinued or dropped out of the study during the 12-week period via visits by health professionals · Usability: standardized interviews and regular phone contact. |
| Fleisher et al. [71] | 2022 | Non-randomized, controlled study | | | · Health-related Quality of Life (QoL) | Mixed | · Health-related Quality of Life (QoL): measured by the Parkinson's Disease Questionnaire-39 (PDQ-39) at home visits |
| Flynn et al. [56] | 2020 | Randomized controlled Pilot study | | | Feasibility, Adherence, Acceptability | Mixed | <ul style="list-style-type: none"> · Feasibility: Measuring the time taken to develop the exercise program · Adherence was determined by recording the number of exercise sessions attempted. · Acceptability was examined using a participant questionnaire about the program, conducted in weeks 5 and 10. Participants were |

| | | | | | | | |
|---------------------|------|----------------------------|--|--|--|-------|--|
| | | | | | | | also interviewed specifically about their experiences of exercise at home and in a center and this will be the topic of a separate report. |
| Gassner et al. [29] | 2022 | Pilot Interventional Study | | | Usability, Feasibility, Impact, Functional status, and Quality of Life (QoL) | Mixed | Usability + Feasibility: System Usability Scale (SUS), Parkinson Disease Questionnaire (PDQ-39) · Impact, Status and QoL: UPDRS-III, Timed Up and Go (TUG) test, 2-minute walking test, and sensor-based gait analysis. |
| Gao et al. [47] | 2021 | double-blind, parallel RCT | | | Effectiveness | Mixed | Measuring overall effect of medication management and rehabilitation training through self-rating scale by patients completing a self-assessment form (WOQ-9 questionnaire, PDQ-39, FOGQ, CSI, MFS, nM-EDL, M-EDL, ADL) |
| Karni et al. [30] | 2022 | Pilot Study | | | · User Interface Evaluation · Patient Empowerment | Mixed | · User Interface: Semi-structured interviews and observations made by task completion · Patient Empowerment: Using the ICT4PEM to formulate ICT strategies |
| Landers et al. [60] | 2020 | Single-Cohort Pilot Study | | | · Feasibility, Safety, and Signal of Efficacy | Mixed | · Feasibility (app usage and usability questions): Participation data (minutes of use) were recorded by the app. Additionally, participants were asked questions about the usability of the app. · Safety (adverse events and falls): Data were tracked via an in-app question every 2 weeks of the 12-week study. Fall data were tracked via an in-app question after every exercise session. · Signal of efficacy: Assessed at baseline, 8 weeks, and 12 weeks using 30-second STS, Timed Up and Go (TUG) and Parkinson's Disease Questionnaire 8 (PDQ8) · The STS and TUG tests were preceded by a demonstration video and an explanation of the test prior to the assessment using a built-in timer. In addition to the STS, TUG, and PDQ8, the Global Rating of Change score was asked at the conclusion of the 12-week study. |
| LoBuono et al. [31] | 2021 | Mixed-methods Study | | | Acceptability, Perception | Mixed | · Acceptability + Perception: Qualitative data was collected through in-person semi-structured, dyadic interviews, and questionnaires from 20 dyads (20 PwPD and their caregivers) · Quantitative data were analyzed using independent samples tests and Fisher's exact tests. Qualitative codes were transformed into variables and compared to digital competence scores to integrate the data. |
| Maggio et al. [61] | 2022 | Pilot Study | | | Feasibility, Usability | Mixed | · System Usability Scale (SUS) consisting of 10 items based on the subjective experience of usability. The items are rated on a 5-point Likert scale ranging from 'strongly agree' to 'strongly disagree.' · Goal Attainment Scaling (GAS) to evaluate the achievement of objectives. The GAS assesses the patient's perception of the goals |

| | | | | | | | |
|-----------------------|------|---------------------------------------|--|--|---|--------------|---|
| | | | | | | | achieved during the intervention. Each goal is agreed upon with the patient and is evaluated on a 5-point scale. |
| Morgan et al. [25] | 2022 | Nonrandomized Qualitative Study | | | Acceptability | Qualitative | Study-specific semi-structured interviews with a cohort of PD and control participants who lived freely for several days in a home-like environment |
| Omberg et al. [68] | 2021 | Observational Study | | | Performance | Quantitative | · Collection of raw data: Finger tapping activity measured dexterity, speed, and abnormality in kinesis (including hastening, faltering and/or freezing), Voice, Walk, Balance. Then compared the mPower symptom severity score with MDS-UPDRS, the SE-ADL and the Hoehn and Yahr score. |
| Ozanne et al. [63] | 2017 | Focus Group Study | | | Perceptions regarding the use of wearables | Qualitative | · Focus group interviews were used to gain a deeper insight into various perceptions through group discussions. The interviews were observed, and mind maps were made. |
| Ozinga et al. [62] | 2017 | Experimental Study | | | Performance | Quantitative | · Postural stability test: Acceleration range (P2P) in multiple movement directions (i.e., ML, AP, and TR) during a variety of sensory conditions while wearing mobile device to waist (level with the sacrum) |
| Pastana et al. [54] | 2023 | RCT | | | Feasibility, Efficacy | Mixed | · Feasibility: Measured by adherence + safety: Adherence was defined as the percentage of sessions attended. Based on the percentage of the sessions attended, participants were categorized as high adherence (>80%), partial adherence (20%–80%), and non-adherence (< 20%). · Safety was evaluated by tracking the cumulative number of AEs and severe AEs from the baseline through the end of follow-up. · Efficacy: Gait and dynamic movements were evaluated by the TUG test, 5STS, and ABC scale. The global motor status was evaluated by MDS-UPDRS Part III. Patient-reported outcomes were evaluated by the PDQ-8. |
| Piro et al. [32] | 2014 | Experimental Study | | | Project Vision, Usability, Interoperability | Mixed | · Project Vision: Inertia sensors and perform standardized motor tasks · Usability/ Interoperability: Expert interviews were conducted with neurologists and collaborations with PD support groups · UPDRS rating by physician based on movement of the avatar |
| Rodriguez et al. [33] | 2023 | Cross-sectional, observational Study: | | | Usability | Mixed | · 5 individuals (PwP, family members, caregivers, students and healthcare professionals) used the app for 5 days and were individually observed using the Think aloud technique. · The System Usability Scale (SUS) questionnaire was used with 10 statements with an intensity measurement from the Likert scale |

| | | | | | | | |
|---------------------|------|-----------------------|--|--|--------------------------------------|-------------|---|
| | | | | | | | of 1–5, where close to 1 refers to strongly disagree, close to 5 strongly agree. |
| Santos et al. [57] | 2022 | Cross-sectional study | | | Feasibility | Qualitative | · Feasibility: Study-specific interview and England Activities of Daily Living (ADL) scale was used. |
| Schmidt et al. [58] | 2022 | RCT | | | Accuracy, patterns of miss reporting | Mixed | · 12-week, home-based upper limb exergame program and analysis providing an objective electronic measure of adherence for comparison with self-report logbooks. |
| Tzallas et al. [66] | 2014 | Pilot trial | | | Accuracy and acceptability | Mixed | · Short-term and long-term recordings from several PD patients, wearability analysis was performed to identify if the wearable multi-sensor monitor unit (WMSMU) is acceptable by patients and how the design could be improved using the Clinician Graphical User Interface (C-GUI) Evaluation. |
| Virmani et al. [65] | 2022 | Feasibility Study | | | Feasibility | Mixed | <ul style="list-style-type: none"> · Modified version of the Unified Parkinson's disease Rating Scale (UPDRS) that excludes the motor assessments of tone (UPDRS item 22) and balance (UPDRS item 30) was utilized. · Freezing of gait determination and quantification for freezing of gait questionnaire (N-FOGQ). · Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) · Handwriting samples were obtained with a Pilot G2 ballpoint pen mailed to participants · Gait was assessed using the Timed-up-and-go test (TUG). · Voice samples were collected using a secure voicemail · REDCap survey instruments were developed for participants to complete the self-filled Parkinson's disease quality of life scale-39 (PDQ-39) · At the completion of their visit, participants were asked to complete a study-specific survey to gauge their satisfaction with the visit and their perception of audio-video quality |
| Xu et al. [59] | 2022 | Survey Study | | | Awareness, Utilization, Satisfaction | Mixed | <ul style="list-style-type: none"> · For all outcome measures survey and questionnaires were used · Descriptive statistics were used to summarize survey responses · Responses to quality questions were compared across different service delivery methods (in-person, video, or phone) using chi-square tests. Fisher's exact test was applied when applicable. |
| Zhang et al. [17] | 2019 | Experimental Study | | | Effectiveness | Mixed | <ul style="list-style-type: none"> · Effectiveness based on: Accuracy, precision, recall · Gait assessment through the on-board sensors of smartphones. |

| | | | | | | | |
|------------------|------|--------------------|--|--|------------------------------|-------|--|
| Zhao et al. [64] | 2016 | Mixed Method Study | | | Motion data, User experience | Mixed | <ul style="list-style-type: none">· Motion data were collected using an MVN motion capture suit· User experience: A study-specific, semi-open interview using a five-point Likert scale and suggestions for future implementations of the app |
|------------------|------|--------------------|--|--|------------------------------|-------|--|